A prospective longitudinal study of Pasireotide in Nelson's syndrome.
Trainer, Peter J
AffiliationDepartment of Oncology and Metabolism, The Medical School, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
MetadataShow full item record
AbstractNelson's syndrome is a challenging condition that can develop following bilateral adrenalectomy for Cushing's disease, with high circulating ACTH levels, pigmentation and an invasive pituitary tumor. There is no established medical therapy. The aim of the study was to assess the effects of pasireotide on plasma ACTH and tumor volume in Nelson's syndrome.
CitationA prospective longitudinal study of Pasireotide in Nelson's syndrome. 2018 Pituitary
- Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog.
- Authors: Katznelson L
- Issue date: 2013 May
- Ineffectiveness of rosiglitazone therapy in Nelson's syndrome.
- Authors: Munir A, Song F, Ince P, Walters SJ, Ross R, Newell-Price J
- Issue date: 2007 May
- Management of Nelson's syndrome: observations in fifteen patients.
- Authors: Kemink SA, Grotenhuis JA, De Vries J, Pieters GF, Hermus AR, Smals AG
- Issue date: 2001 Jan
- Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson's syndrome compared with Cushing's disease.
- Authors: van Aken MO, Pereira AM, van den Berg G, Romijn JA, Veldhuis JD, Roelfsema F
- Issue date: 2004 Jun
- Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome.
- Authors: Assié G, Bahurel H, Coste J, Silvera S, Kujas M, Dugué MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X
- Issue date: 2007 Jan